<?xml version="1.0" encoding="UTF-8"?>
<p>First of all, the expression and activity of two important factors may be considered, namely, ACE2 and the 
 <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2421" xmlns:xlink="http://www.w3.org/1999/xlink">transmembrane protease, serine 2</ext-link> (TMPRSS2; Cheng et al., 
 <xref rid="bph15207-bib-0016" ref-type="ref">2015</xref>; Kuba et al., 
 <xref rid="bph15207-bib-0052" ref-type="ref">2005</xref>). While ACE2 is the receptor for the 
 <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3114" xmlns:xlink="http://www.w3.org/1999/xlink">spike (S) protein</ext-link> of coronaviruses, TMPRSS2 splits the S‐protein at sites S1/S2 and S2, favouring the attachment and fusion of the virus to cell membranes, respectively. ACE2 is largely expressed in organs mainly targeted and damaged by SARS‐CoV‐2 (Pagliaro &amp; Penna, 
 <xref rid="bph15207-bib-0063" ref-type="ref">2005</xref>). Both ACE2 and TMPRSS2 have been proposed as modulators of the different susceptibility to SARS‐CoV in both sexes (Hoffmann et al., 
 <xref rid="bph15207-bib-0037" ref-type="ref">2020</xref>).
</p>
